Hangzhou Tigermed Consulting Co., Ltd (SHE:300347)
China · Delayed Price · Currency is CNY 50.00
+0.33 (0.66%)
Nov 2, 2026, 2:25 PM CST
SHE:300347 Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Revenue Revenue Growth | 7,598 | 6,833 | 6,603 | 7,384 | 7,085 | 5,214 |
Revenue Growth | 15.81% | 3.48% | -10.58% | 4.21% | 35.91% | 63.32% |
Gross Profit Gross Profit Growth | 1,992 | 1,873 | 2,244 | 2,845 | 2,808 | 2,271 |
Operating Income Operating Income Growth | 733.36 | 608.47 | 1,009 | 1,690 | 1,763 | 1,344 |
Net Income Net Income Growth | -404.59 | 887.89 | 405.14 | 2,025 | 2,007 | 2,874 |
Earnings Per Share EPS Growth | -0.48 | 1.04 | 0.47 | 2.34 | 2.32 | 3.30 |
EPS Growth | - | 120.99% | -79.94% | 0.86% | -29.70% | 50.69% |
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Clinical trial technical services Clinical trial technical services Growth | 3,267 | 3,178 | 4,168 | 4,125 | 2,994 |
Clinical Trial Related and Laboratory Services Clinical Trial Related and Laboratory Services Growth | 3,447 | 3,296 | 3,121 | 2,876 | 2,194 |
Unallocated Other Business Unallocated Other Business Growth | 119.47 | 129.04 | 94.93 | 83.93 | 26.17 |
Total Total Growth | 6,833 | 6,603 | 7,384 | 7,085 | 5,214 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Investments Cash & Investments Growth | 2,118 | 1,837 | 2,145 | 7,503 | 7,883 | 8,574 |
Total Debt Total Debt Growth | 2,218 | 1,676 | 2,834 | 3,347 | 2,720 | 973.67 |
Net Cash (Debt) Net Cash Growth | -99.45 | 160.75 | -688.64 | 4,157 | 5,163 | 7,600 |
Net Cash Growth | - | - | - | -19.50% | -32.06% | -22.60% |
Net Cash Per Share Net Cash Per Share Growth | -0.12 | 0.19 | -0.80 | 4.81 | 5.97 | 8.73 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Cash Flow Operating Cash Flow Growth | 1,150 | 1,118 | 1,097 | 1,150 | 1,358 | 1,424 |
Capital Expenditures CapEx Growth | -171.93 | -214.37 | -356.55 | -313.76 | -448.6 | -368.62 |
Free Cash Flow Free Cash Flow Growth | 977.91 | 903.72 | 740.45 | 836.68 | 908.9 | 1,055 |
Free Cash Flow Growth | -2.76% | 22.05% | -11.50% | -7.95% | -13.86% | 25.29% |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Gross Margin | 26.21% | 27.41% | 33.99% | 38.53% | 39.64% | 43.55% |
Operating Margin | 9.65% | 8.91% | 15.29% | 22.89% | 24.88% | 25.77% |
Pretax Margin | -2.76% | 14.68% | 10.06% | 33.70% | 36.49% | 70.67% |
Profit Margin | -5.33% | 13.00% | 6.14% | 27.42% | 28.32% | 55.13% |
FCF Margin | 12.87% | 13.23% | 11.21% | 11.33% | 12.83% | 20.24% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Dividend Per Share Dividend Per Share Growth | 0.126 | 0.126 | 0.300 | 0.568 | 0.550 | 0.500 |
Dividend Per Share Growth | -58.00% | -58.00% | -47.18% | 3.27% | 10.00% | 66.67% |
Dividend Yield | 0.25% | 0.23% | 0.59% | 1.10% | 0.55% | 0.42% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | - | 52.05 | 108.31 | 22.13 | 43.64 | 36.25 |
Forward PE | 48.27 | 48.80 | 28.29 | 19.90 | 32.89 | 48.60 |
P/FCF Ratio | 40.17 | 51.14 | 59.27 | 53.55 | 96.34 | 98.75 |
PS Ratio | 5.17 | 6.76 | 6.65 | 6.07 | 12.36 | 19.99 |